Nitto Avecia

Pharmaceutical Manufacturing • Milford, Massachusetts, United States • 501-1000 Employees

Company overview

Headquarters	Milford, Massachusetts, United States
Phone number	+15136793000
Website	avecia.com
NAICS	3254
SIC	283
Keywords	Analytical Services, Process Validation (Oligonucleotide), Stability Services
Employees	501-1000
Socials

Key Contacts at Nitto Avecia

Brian Murphy

Associate Director Of Operational Excellence

Kenneth M. Jones

Director Environment Health Safety

Michael Postlethwaite

Senior Director Business Development Europe

Brian Potorski

Director Of Quality Control

Sal Ally

Sr. Director Of Manufacturing Operations

Michael Amend

Director, Hr Operations And Talent Management

Marc Gomez Caminals

Director Of Business Development

Anna Nielander

Associate Director

Robert Coulter

Director Facilities Engineering

Scott Suttill

Director Of Quality And Regulatory Compliance

Nitto Avecia Email Formats

Nitto Avecia uses 2 email formats. The most common is {first name}.{last name} (e.g., john.doe@avecia.com), used 49.8% of the time.

Format	Example	Percentage
{first name}.{last name}	john.doe@avecia.com	49.8%
{first initial}.{last name}	j.doe@avecia.com	48.2%

About Nitto Avecia

Oligonucleotides are giving rise to a new generation of therapeutics—and Nitto Avecia is helping lead the way. With more than 25 years’ experience in oligonucleotide development and production, we are the partner of choice for pharmaceutical innovators creating new drugs with the power to transform treatment for a wide range of diseases. In partnership with Nitto Avecia Pharma Services, Nitto Avecia is the first CMO that offers a comprehensive, end-to-end oligonucleotide solution. This offers the advantage of a single, expert partner handling the entire process—from drug substance through drug product manufacturing—with flexible solutions and consistent reliability and quality.

Nitto Avecia revenue & valuation

Annual revenue	$36,200,000
Revenue per employee	$59,000
Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues	$115,900,000
Total funding	No funding